Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2023-12-20 | Reverse | 1:10 |
Canopy Growth Corporation produces, distributes, and sells cannabis and hemp products for recreational and medical use across Canada, the U.S., and Germany, operating through two segments with a diverse brand portfolio.
Canopy Growth offers high-potency pre-rolled joints infused with liquid and THCA diamonds, exceeding 60% THC, showcasing their focus on innovation in the growing infused pre-roll market.
In late 2025, reports that the White House was considering an executive order to reclassify marijuana as a less dangerous drug sent shockwaves through the cannabis industry, putting Canopy Growth squarely in the spotlight. This potential regulatory shift in the United States, a key target market for the company, triggered a significant rally in its stock price as investors speculated on the positive implications for the business, including potential tax benefits and easier access to banking services.
Canopy Growth announced a definitive agreement to acquire Montreal-based MTL Cannabis in a transaction valued at approximately $125 million. This strategic acquisition is expected to position Canopy as the leader in the Canadian medical cannabis market and leverage MTL's renowned cultivation expertise to enhance high-quality flower supply for both Canadian and international markets.
A Q1 FY2027 revenue record from Tilray Brands (NASDAQ:TLRY) is drawing heavy selling, because the segment that built the company's following moved the wrong way. Tilray Brands shares are at $3.
Canopy Growth Corporation (CGC) concluded the recent trading session at $0.87, signifying a -1.87% move from its prior day's close.
Canopy Growth burned through a significant amount of cash last quarter. The company's poor financials are a big reason why the stock has cratered.
Canopy Growth Corporation (CGC) reached $0.88 at the closing of the latest trading day, reflecting a -1.54% change compared to its last close.
Shares of Canopy Growth Corporation (NASDAQ: CGC - Get Free Report) have been given an average rating of "Hold" by the five analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
 IRWD | $3.88 | COMPARE |
 ACRS | $3.73 | COMPARE |
 TKNO | $8.56 | COMPARE |
 CABA | $1.92 | COMPARE |
 ACB | $4.43 | COMPARE |
 LFCR | $6.43 | COMPARE |
 BIOA | $6.14 | COMPARE |
 LYEL | $8.66 | COMPARE |
